Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries

被引：1

作者：

Lee, C-K. ^{[1
]}

Yoo, C. ^{[2
]}

Park, S. J. ^{[3
]}

Kim, H. ^{[4
,17
]}

Korphaisarn, K. ^{[5
]}

Kim, J. W. ^{[6
,11
]}

Chen, S-C. ^{[7
]}

Kim, I. ^{[8
]}

Kim, M. ^{[9
]}

Chan, S. L. ^{[10
]}

Kim, J. W. ^{[6
,11
]}

Tai, D. W. M. ^{[12
]}

Oh, S. B. ^{[13
]}

Chen, C-T. ^{[14
]}

Bae, W. K. ^{[15
,16
]}

Kim, H. ^{[4
,17
]}

Hong, J. Y. ^{[18
]}

Choi, H. J. ^{[1
,19
]}

Chon, H. J.

Lee, M. A. ^{[20
]}

机构：

[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[3] Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[4] Ulsan Univ Hosp, Div Hematol Oncol, Dept Internal Med, Ulsan, South Korea

[5] Mahidol Univ, Fac Med, Div Med Oncol, Dept Med,Siriraj Hosp, Bangkok, Thailand

[6] Seoul Natl Univ, Internal Med, Bundang Hosp, Seongnam, South Korea

[7] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan

[8] Inje Univ, Div Oncol, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea

[9] Gangneung Asan Hosp, Med Oncol Dept, Kangnung, South Korea

[10] Chinese Univ Hong Kong, Clin Oncol Dept, Sha Tin, Sino Bldg, Hong Kong, Peoples R China

[11] Korea Univ Anam Hosp, Dept Hemato oncol, Seoul, South Korea

[12] NCCS Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[13] Pusan Natl Univ, Internal Med, Yangsan Hosp, Yangsan, South Korea

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Hsin Chu Branch, Hsinchu, Taiwan

[15] Chonnam Natl Univ, Div Hematol & Oncol, Med Sch, Hwasun, South Korea

[16] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[17] Chonnam Natl Univ Hwasun Hosp, Hwasun, South Korea

[18] Chungbuk Natl Univ Hosp, Hematol Oncol, Cheonju-si, South Korea

[19] Samsung Med Ctr SMC, Div Hematol Oncol, Seoul, South Korea

[20] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

970P

引用

页码：S603 / S603

页数：1

共 50 条

[1] Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
Lee, Choong-kun
Yoo, Changhoon
Hong, Jung Yong
Park, Se Jun
Kim, Jin Won
Tai, David Wai Meng
Kim, Hyeyeong
Korphaisarn, Krittiya
Tanasanvimon, Suebpong
Chen, San-Chi
Kim, Ju Won
Kim, Ilhwan
Kim, Moonho
Choo, Joan
Oh, Sang-Bo
Chen, Ching-Tso
Bae, Woo Kyun
Kim, Hongsik
Huh, Seok Jae
Yen, Chia-Jui
Park, Sejung
Lee, Dong Ki
Chan, Landon Long
Kang, Beodeul
Kang, Minsu
Sundar, Raghav
Choi, Hye Jin
Chan, Stephen Lam
Chon, Hong Jae
Lee, Myung-Ah
LIVER CANCER, 2024,
[2] Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Kim, Beom Kyung
Cheon, Jaekyung
Kim, Hyeyeong
Kang, Beodeul
Ha, Yeonjung
Kim, Do Young
Hwang, Seong Gyu
Chon, Young Eun
Chon, Hong Jae
CANCERS, 2022, 14 (07)
[3] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Boonkaya, Sangdao
Thanapirom, Kessarin
Siripon, Nipaporn
Thaimai, Panarat
Ananchuensook, Prooksa
Sriphoosanaphan, Supachaya
Tanasanvimon, Surbpong
Treeprasertsuk, Sombat
Komolmit, Piyawat
GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
[4] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
Brown, Timothy J.
Mamtani, Ronac
Gimotty, Phyllis A.
Karasic, Thomas B.
Yang, Yu-Xiao
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
[5] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
Timothy J. Brown
Ronac Mamtani
Phyllis A. Gimotty
Thomas B. Karasic
Yu-Xiao Yang
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
[6] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
Storandt, Michael H.
Zemla, Tyler J.
Patell, Kanchi
Naleid, Nikolas
Gile, Jennifer J.
Tran, Nguyen H.
Chakrabarti, Sakti
Jin, Zhaohui
Borad, Mitesh
Mahipal, Amit
ONCOLOGIST, 2024, 29 (11): : 986 - 996
[7] Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
Singal, A. G.
Ozgurdal, K.
Fan, X.
Vassilev, Z.
Chen, C-C.
Multani, J. K.
Zhou, Z.
He, J.
Pisa, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867
[8] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
Wang, Bi-Cheng
Kuang, Bo-Hua
Lin, Guo-He
TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
[9] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
Bi-Cheng Wang
Bo-Hua Kuang
Guo-He Lin
Targeted Oncology, 2024, 19 : 203 - 212
[10] Real-world experience with atezolizumab plus bevacizumab in the management of nonresectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.
Devarkonda, Vishal
Byreddi, Laxman Yashwant
Balmuri, Shravya
Gudi, Thulasi
Gaddam, Shiva Jashwanth
Keerty, Dinesh
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →